Kodiak’s KSI-101 Yields +17.8-Letter Gain, Spurs Phase 3 Asia Expansion
Kodiak’s KSI-101 achieved ≥15-letter gains in 58% of Asian MESI patients and a mean BCVA increase of +17.8 letters at Week 24, with central subfield thickness reduced below 325 µm after one injection. Consistent anatomic and visual outcomes in tertiary care and U.S. Phase 1b cohorts support Phase 3 PEAK and PINNACLE expansion into Asia.
1. KSI-101 Clinical Outcomes
In the Phase 1b APEX study and a tertiary care uveitis cohort, KSI-101 demonstrated robust efficacy in macular edema secondary to inflammation. Patients achieved a mean BCVA gain of +17.8 letters, ≥15-letter improvements in 58% of Asian subjects, and rapid resolution of IRF and SRF by Week 8, with central subfield thickness falling below 325 µm after a single injection.
2. Phase 3 Program Expansion
Positive consistency between U.S. and Asian cohort outcomes has reinforced Kodiak’s decision to advance 5 mg and 10 mg dose levels into global Phase 3 studies PEAK and PINNACLE. Results suggest applicability across diverse patient populations and underlying etiologies, paving the way for trials in Asia and other regions.
3. ABCD Platform Progress
Kodiak’s ABCD Platform™, an evolution of its ABC system, integrates small-molecule and biologic conjugation to enable targeted, multi-modal therapies. This versatile platform underpins ongoing pipeline programs in retinal and glaucoma optic neuropathy indications, addressing limitations of current single-target treatments.